215 related articles for article (PubMed ID: 32080261)
1. Rational design of novel benzisoxazole derivatives with acetylcholinesterase inhibitory and serotoninergic 5-HT
Lalut J; Payan H; Davis A; Lecoutey C; Legay R; Sopkova-de Oliveira Santos J; Claeysen S; Dallemagne P; Rochais C
Sci Rep; 2020 Feb; 10(1):3014. PubMed ID: 32080261
[TBL] [Abstract][Full Text] [Related]
2. Novel multitarget-directed ligands (MTDLs) with acetylcholinesterase (AChE) inhibitory and serotonergic subtype 4 receptor (5-HT4R) agonist activities as potential agents against Alzheimer's disease: the design of donecopride.
Rochais C; Lecoutey C; Gaven F; Giannoni P; Hamidouche K; Hedou D; Dubost E; Genest D; Yahiaoui S; Freret T; Bouet V; Dauphin F; Sopkova de Oliveira Santos J; Ballandonne C; Corvaisier S; Malzert-Fréon A; Legay R; Boulouard M; Claeysen S; Dallemagne P
J Med Chem; 2015 Apr; 58(7):3172-87. PubMed ID: 25793650
[TBL] [Abstract][Full Text] [Related]
3. Design of donecopride, a dual serotonin subtype 4 receptor agonist/acetylcholinesterase inhibitor with potential interest for Alzheimer's disease treatment.
Lecoutey C; Hedou D; Freret T; Giannoni P; Gaven F; Since M; Bouet V; Ballandonne C; Corvaisier S; Malzert Fréon A; Mignani S; Cresteil T; Boulouard M; Claeysen S; Rochais C; Dallemagne P
Proc Natl Acad Sci U S A; 2014 Sep; 111(36):E3825-30. PubMed ID: 25157130
[TBL] [Abstract][Full Text] [Related]
4. Novel multitarget-directed ligands targeting acetylcholinesterase and σ
Lalut J; Santoni G; Karila D; Lecoutey C; Davis A; Nachon F; Silman I; Sussman J; Weik M; Maurice T; Dallemagne P; Rochais C
Eur J Med Chem; 2019 Jan; 162():234-248. PubMed ID: 30447434
[TBL] [Abstract][Full Text] [Related]
5. Development of Novel Potential Pleiotropic Compounds of Interest in Alzheimer's Disease Treatment through Rigidification Strategy.
Lecoutey C; Legay R; Davis A; Sopková-de Oliveira Santos J; Dallemagne P; Rochais C
Molecules; 2021 Apr; 26(9):. PubMed ID: 33926141
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, in vitro evaluation and molecular docking of a new class of indolylpropyl benzamidopiperazines as dual AChE and SERT ligands for Alzheimer's disease.
Rodríguez-Lavado J; Gallardo-Garrido C; Mallea M; Bustos V; Osorio R; Hödar-Salazar M; Chung H; Araya-Maturana R; Lorca M; Pessoa-Mahana CD; Mella-Raipán J; Saitz C; Jaque P; Reyes-Parada M; Iturriaga-Vásquez P; Pessoa-Mahana H
Eur J Med Chem; 2020 Jul; 198():112368. PubMed ID: 32388114
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, in vitro and in vivo evaluation of novel pyrrolizine-based compounds with potential activity as cholinesterase inhibitors and anti-Alzheimer's agents.
El-Sayed NA; Farag AE; Ezzat MAF; Akincioglu H; Gülçin İ; Abou-Seri SM
Bioorg Chem; 2019 Dec; 93():103312. PubMed ID: 31586715
[TBL] [Abstract][Full Text] [Related]
8. Design, Synthesis, and In Vitro Evaluation of Hydroxybenzimidazole-Donepezil Analogues as Multitarget-Directed Ligands for the Treatment of Alzheimer's Disease.
Chaves S; Resta S; Rinaldo F; Costa M; Josselin R; Gwizdala K; Piemontese L; Capriati V; Pereira-Santos AR; Cardoso SM; Santos MA
Molecules; 2020 Feb; 25(4):. PubMed ID: 32098407
[TBL] [Abstract][Full Text] [Related]
9. The novel therapeutic strategy of vilazodone-donepezil chimeras as potent triple-target ligands for the potential treatment of Alzheimer's disease with comorbid depression.
Li X; Li J; Huang Y; Gong Q; Fu Y; Xu Y; Huang J; You H; Zhang D; Zhang D; Mao F; Zhu J; Wang H; Zhang H; Li J
Eur J Med Chem; 2022 Feb; 229():114045. PubMed ID: 34922191
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of donepezil analogues as dual AChE and BACE-1 inhibitors.
Gabr MT; Abdel-Raziq MS
Bioorg Chem; 2018 Oct; 80():245-252. PubMed ID: 29966870
[TBL] [Abstract][Full Text] [Related]
11. Design and Synthesis of Novel Arylisoxazole-Chromenone Carboxamides: Investigation of Biological Activities Associated with Alzheimer's Disease.
Saeedi M; Rastegari A; Hariri R; Mirfazli SS; Mahdavi M; Edraki N; Firuzi O; Akbarzadeh T
Chem Biodivers; 2020 May; 17(5):e1900746. PubMed ID: 32154628
[TBL] [Abstract][Full Text] [Related]
12. De-novo Drug Design, Molecular Docking and In-Silico Molecular Prediction of AChEI Analogues through CADD Approaches as Anti-Alzheimer's Agents.
Pandey S; Singh BK
Curr Comput Aided Drug Des; 2020; 16(1):54-72. PubMed ID: 30827255
[TBL] [Abstract][Full Text] [Related]
13. Design, Synthesis, and Evaluation of Acetylcholinesterase and Butyrylcholinesterase Dual-Target Inhibitors against Alzheimer's Diseases.
Guo Y; Yang H; Huang Z; Tian S; Li Q; Du C; Chen T; Liu Y; Sun H; Liu Z
Molecules; 2020 Jan; 25(3):. PubMed ID: 31979317
[TBL] [Abstract][Full Text] [Related]
14. Discovery of new acetylcholinesterase inhibitors for Alzheimer's disease: virtual screening and
David B; Schneider P; Schäfer P; Pietruszka J; Gohlke H
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):491-496. PubMed ID: 33478277
[TBL] [Abstract][Full Text] [Related]
15. Multitarget Strategy to Address Alzheimer's Disease: Design, Synthesis, Biological Evaluation, and Computational Studies of Coumarin-Based Derivatives.
Montanari S; Bartolini M; Neviani P; Belluti F; Gobbi S; Pruccoli L; Tarozzi A; Falchi F; Andrisano V; Miszta P; Cavalli A; Filipek S; Bisi A; Rampa A
ChemMedChem; 2016 Jun; 11(12):1296-308. PubMed ID: 26507467
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological evaluation of potential acetylcholinesterase inhibitors based on a benzoxazine core.
Méndez-Rojas C; Quiroz G; Faúndez M; Gallardo-Garrido C; Pessoa-Mahana CD; Chung H; Gallardo-Toledo E; Saitz-Barría C; Araya-Maturana R; Kogan MJ; Zúñiga-López MC; Iturriaga-Vásquez P; Valenzuela-Gutiérrez C; Pessoa-Mahana H
Arch Pharm (Weinheim); 2018 May; 351(5):e1800024. PubMed ID: 29611620
[TBL] [Abstract][Full Text] [Related]
17. Isoxazoles: synthesis, evaluation and bioinformatic design as acetylcholinesterase inhibitors.
Gutiérrez M; Matus MF; Poblete T; Amigo J; Vallejos G; Astudillo L
J Pharm Pharmacol; 2013 Dec; 65(12):1796-804. PubMed ID: 24180424
[TBL] [Abstract][Full Text] [Related]
18. Claulansine F-Donepezil Hybrids as Anti-Alzheimer's Disease Agents with Cholinergic, Free-Radical Scavenging, and Neuroprotective Activities.
Zang Y; Liu K; Wang W; Li C; Ma J; Yang J; Chen X; Wang X; Zhang D
Molecules; 2021 Feb; 26(5):. PubMed ID: 33671020
[TBL] [Abstract][Full Text] [Related]
19. Rational design of new multitarget histamine H
Łażewska D; Bajda M; Kaleta M; Zaręba P; Doroz-Płonka A; Siwek A; Alachkar A; Mogilski S; Saad A; Kuder K; Olejarz-Maciej A; Godyń J; Stary D; Sudoł S; Więcek M; Latacz G; Walczak M; Handzlik J; Sadek B; Malawska B; Kieć-Kononowicz K
Eur J Med Chem; 2020 Dec; 207():112743. PubMed ID: 32882609
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and anti-Alzheimer's disease activity study of xanthone derivatives based on multi-target strategy.
Kou X; Song L; Wang Y; Yu Q; Ju H; Yang A; Shen R
Bioorg Med Chem Lett; 2020 Feb; 30(4):126927. PubMed ID: 31901382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
